GeneStrat® genomic testing is a laboratory test service that determines the presence of somatic genetic variants in circulating nucleic acids (DNA and RNA) from the plasma of patients with lung cancer using ddPCR (Droplet Digital™ Polymerase Chain Reaction. GeneStrat solely reports the presence or absence of certain, limited genomic alterations which may be useful for physicians when
considering different therapeutic options. The mutations detected using GeneStrat account for a large proportion of variants found in NSCLC, including EGFR (89% coverage), ALK (78%), ROS1 (88%), RET (99%), KRAS (78%), and BRAF (54%). This includes the EGFR T790M mutation, which is a marker of resistance to anti-EGFR drugs. According to Biodesix, turaround time for the test is 72 hours.